The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

European pharmaceutical giant Novo Nordisk (NVO) has struck a licensing deal with U.S. biotech firm Septerna (SEPN) to ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...